Skip to main content

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region

Written by Customer Service on . Posted in Public Companies.

Japan represents third largest non-surgical medical aesthetic market in the world

SAN CLEMENTE, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted the Company approval to commercially market Sofwave’s SUPERB™ Technology. Market approval in Japan further extends Sofwave’s sales reach in the APAC territories, which now comprises major regional medical aesthetic device markets, including Japan, Australia, Taiwan, and South Korea.

“We are delighted to broaden Sofwave’s commercial reach to Japan in 2025, which now enables us to sell additional devices across major markets in the APAC region,” said Sofwave’s Chief Executive Officer Louis Scafuri. “Receipt of regulatory approval in Japan, one of the world’s largest medical technology markets, represents a significant growth opportunity to expand both device sales and brand awareness, which are both being driven worldwide by the fast adoption of GLP1-inverse agonist weight loss medications, aging populations and the increasing demand for minimally invasive medical aesthetic procedures. With a strong go-to-market strategy, including a growing distribution network, dedicated in-house sales, marketing, and field force teams, as well as increasing consumer awareness supported by traditional, digital, and social media marketing campaigns, we look forward to continuing to expand Sofwave’s commercial footprint.”

According to the International Society of Aesthetic Plastic Surgery’s (ISAPS) most recent global surveys, conducted in 2023 and 2024, Japan represented the third largest non-surgical medical aesthetic procedures market worldwide in 2022 and had the third highest number of plastic surgeons of all ranked countries worldwide in 2023.

About Sofwave Medical Ltd.
Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using its proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology, is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin), to improve the appearance of skin laxity on the upper arms, as well as the short-term improvement in the appearance of cellulite and treatment of acne scars. The Company’s Pure Impact™ module uses 4th generation EMS technology and is cleared for muscle toning. Sofwave’s products provide physicians with smart yet simple, effective, and safe aesthetic solutions for their patients. Contact: Info@sofwave.com

Investor Contact:
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
britchie@lifesciadvisors.com

Source:
https://www.isaps.org/media/rxnfqibn/isaps-global-survey_2023.pdf
https://www.isaps.org/media/a0qfm4h3/isaps-global-survey_2022.pdf

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.